Wednesday, July 02, 2025 Published in the NEJM Evidence this is a secondary pooled analysis including the HD6 trial patient data to develop a predictive model. A predictive model for early-stage classic Hodgkin’s lymphoma (cHL) does not exist. Leveraging patient-level data from large clinical trials and registries, researchers developed and validated a model that they term the Early-Stage cHL International Prognostication Index (E-HIPI) to predict 2-year progression-free survival (PFS). Rodday AM, Evens AM, Maurer MJ, Upshaw JN, Counsell N, Rossetti S, Chang C, Cui Z, Xiang Q, Mwangi R, Advani R, Andre M, Gallamini A, Hay AE, Hodgson DC, Hoppe RT, Hutchings M, Johnson P, Mou E, Opat S, Raemaekers J, Savage K, Parsons SK, Radford J. An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma (ONLINE). NEJM Evidence 2025.https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500115
